Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aspirin may slow recurrence in breast cancer patients

14.08.2014

UT Health Science Center San Antonio oncologist reveals findings

New findings published today in the journal Cancer Research reveal that some postmenopausal overweight breast cancer patients who use common anti-inflammatory drugs like aspirin or ibuprofen have significantly lower breast cancer recurrence rates.


Research by Andrew Brenner, M.D., Ph.D., oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, reveals some postmenopausal overweight breast cancer patients who use common anti-inflammatory drugs have significantly lower breast cancer recurrence rates.

Credit: Cancer Therapy & Research Center

Researchers from the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and the University of Texas at Austin began by examining blood serum from CTRC breast cancer patients, said CTRC oncologist Andrew Brenner, M.D., Ph.D.

Studying Blood Serum

... more about:
»Aspirin »COX2 »CTRC »Cancer »Health »breast »drugs

They placed the serum in a culture of fat cells that make estrogen, and then placed the serum on breast cancer cells. The serum from overweight and obese patients caused the cancer cells to grow much more aggressively than the serum from patients who were not overweight.

"It looks like the mechanism is prostaglandins, which have a role in inflammation, and there's more of it in the obese patient serum," Dr. Brenner said.

Based on those findings, the researchers did a retrospective study on patients from the CTRC and the START Center for Cancer Care. They were segregated into those taking COX2 inhibitors (aspirin or ibuprofen) and those who did not.

Finding a Lower Recurrence Rate

"Patients who were on COX2 inhibitors tended to have a lower recurrence rate," Dr. Brenner said.

Anti-inflammatory use reduced the recurrence rate of ERα positive breast cancer by 50 percent and extended patients' disease-free period by more than two years. ER positive breast cancers, cancers that grow in response to exposure to the hormone estrogen, are among the most common form of the disease, accounting for approximately 75 percent of diagnoses.

Cancer researcher Linda deGraffenried, Ph.D., from The University of Texas at Austin, designed the study, working closely with Dr. Brenner and Murali Beeram, M.D., a cancer specialist from the START Center.

The investigators caution that these results are preliminary.

"Overweight or obese women diagnosed with breast cancer are facing a worse prognosis than normal-weight women," said Dr. deGraffenried, who is also adjunct assistant professor in the Department of Cellular and Structural Biology at the Health Science Center.

Facing a Different Disease

"We believe that obese women are facing a different disease. There are changes at the molecular level. We want to reduce the disease-promoting effects of obesity." Based on those results, the CTRC has launched a pilot anti-inflammatory trial in a joint venture with UT Austin, and the research partners are seeking funding for a larger study.

"We would like to identify which women are most likely to benefit from interventions like adding NSAIDs to treatment regimens," Dr. deGraffenried said.

###

The study published in Cancer Research was funded by the United States Department of Defense, Breast Cancer Research Program (W81XWH-11-1-0132) and by the National Cancer Institute (CA054174).

For current news from the UT Health Science Center, please visit our news release website or follow us on Twitter @uthscsa and Facebook.

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the elite academic cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only four in Texas. A leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development (IDD) conducts one of the largest oncology Phase I clinical drug programs in the world, and participates in development of cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit http://www.ctrc.net.

Catherine Duncan | Eurek Alert!

Further reports about: Aspirin COX2 CTRC Cancer Health breast drugs

More articles from Health and Medicine:

nachricht An experimental Alzheimer's drug reverses genetic changes thought to spur the disease
04.05.2016 | Rockefeller University

nachricht Research points to a new treatment for pancreatic cancer
04.05.2016 | Purdue University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nuclear Pores Captured on Film

Using an ultra fast-scanning atomic force microscope, a team of researchers from the University of Basel has filmed “living” nuclear pore complexes at work for the first time. Nuclear pores are molecular machines that control the traffic entering or exiting the cell nucleus. In their article published in Nature Nanotechnology, the researchers explain how the passage of unwanted molecules is prevented by rapidly moving molecular “tentacles” inside the pore.

Using high-speed AFM, Roderick Lim, Argovia Professor at the Biozentrum and the Swiss Nanoscience Institute of the University of Basel, has not only directly...

Im Focus: 2+1 is Not Always 3 - In the microworld unity is not always strength

If a person pushes a broken-down car alone, there is a certain effect. If another person helps, the result is the sum of their efforts. If two micro-particles are pushing another microparticle, however, the resulting effect may not necessarily be the sum their efforts. A recent study published in Nature Communications, measured this odd effect that scientists call “many body.”

In the microscopic world, where the modern miniaturized machines at the new frontiers of technology operate, as long as we are in the presence of two...

Im Focus: Tiny microbots that can clean up water

Researchers from the Max Planck Institute Stuttgart have developed self-propelled tiny ‘microbots’ that can remove lead or organic pollution from contaminated water.

Working with colleagues in Barcelona and Singapore, Samuel Sánchez’s group used graphene oxide to make their microscale motors, which are able to adsorb lead...

Im Focus: ORNL researchers discover new state of water molecule

Neutron scattering and computational modeling have revealed unique and unexpected behavior of water molecules under extreme confinement that is unmatched by any known gas, liquid or solid states.

In a paper published in Physical Review Letters, researchers at the Department of Energy's Oak Ridge National Laboratory describe a new tunneling state of...

Im Focus: Bionic Lightweight Design researchers of the Alfred Wegener Institute at Hannover Messe 2016

Honeycomb structures as the basic building block for industrial applications presented using holo pyramid

Researchers of the Alfred Wegener Institute (AWI) will introduce their latest developments in the field of bionic lightweight design at Hannover Messe from 25...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

The “AC21 International Forum 2016” is About to Begin

27.04.2016 | Event News

Soft switching combines efficiency and improved electro-magnetic compatibility

15.04.2016 | Event News

Grid-Supportive Buildings Give Boost to Renewable Energy Integration

12.04.2016 | Event News

 
Latest News

New fabrication and thermo-optical tuning of whispering gallery microlasers

04.05.2016 | Physics and Astronomy

Introducing the disposable laser

04.05.2016 | Physics and Astronomy

A new vortex identification method for 3-D complex flow

04.05.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>